Bio-Rad Laboratories, Inc. Class A Common Stock vs SMX Security Matters plc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.34 (market cap $8.04B), while SMX Security Matters plc trades at $19 (market cap $17.11M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 469.9× SMX Security Matters plc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| BIO | SMX | |
|---|---|---|
Market Cap | $8.04B | $17.11M |
Sector | Health | Technology |
52-Week High | $339.75 | $295.56K |
52-Week Low | $241.71 | $12.87 |
Enterprise Value | $7.85B | $14.08M |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
SMX trades at $16.21, up 3.58% today, amid neutral technical signals and recent reverse stock splits. The company is positioning itself in the recycling technology space with its Circularity-as-a-Service platform, targeting demand from new state recycling mandates. However, financial metrics show significant challenges with negative ROE of -2,216.26% and ROA of -398.22%, indicating substantial profitability concerns despite a reasonable P/B ratio of 1.93.
The outlook remains speculative with potential upside from regulatory tailwinds in recycling verification technology, but high execution risk given current negative profitability. Investors face substantial dilution risk from recent reverse splits and need to monitor the company's ability to convert regulatory opportunities into sustainable revenue growth.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →